Castle Biosciences CEO Derek J. Maetzold trims stake by 14,496 shares worth $512,445.26
Bitget2026/09/23 20:27- Castle Biosciences CEO Derek J. Maetzold exercised stock options for 8,580 shares at $2.39 on Sept. 21, 2026.
- He sold 8,580 shares at a weighted-average $35.33, cutting his direct stake to 21,479 shares.
- Separate sales of 3,198 shares, 2,718 shares were reported from trusts tied to Maetzold at $35.33.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
